Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: Results of the BRIDGE trial

Leukemia

Volumn 30, Issue 2, 2016, Pages 261-267

  Middeke, J M ^a   Herbst, R ^b   Parmentier, S ^c   Bug, G ^d   Hanel M ^b   Stuhler, G ^e   Schafer Eckart K ^f   Rosler W ^g   Klein, S ^h   Bethge, W ⁱ   Bitz, U ^j   Buttner B ^a   Knoth, H ^a   Alakel, N ^a   Schaich, M ^c   Morgner, A ^b   Kramer, M ^a   Sockel, K ^a   Von Bonin, M ^a,k   Stolzel F ^a   Platzbecker, U ^a   Rollig C ^a   Thiede, C ^a   Ehninger, G ^a   Bornhauser M ^a   Schetelig, J ^a,l   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c Rems Murr Klinikum Winnenden   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e DKD Helios Klinik Wiesbaden   (Germany)

^f KLINIKUM NÜRNBERG   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j HELIOS Klinikum Bad Saarow   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l DKMS German Bone Marrow Donor Center   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLOFARABINE; CYCLOSPORIN A; CYTARABINE; MELPHALAN; MYCOPHENOLATE MOFETIL; THYMOCYTE ANTIBODY; ADENINE NUCLEOTIDE; ANTINEOPLASTIC ANTIMETABOLITE; ARABINONUCLEOSIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLAST CELL; BONE MARROW; BONE MARROW APLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFESTATION; INJURY; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SALVAGE THERAPY; SEPSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PROSPECTIVE STUDY; RECURRENT DISEASE;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84959328694     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.226     Document Type: Article

References (31)

1. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
2. Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol 2013; 26: 253-259.
3. Litzow MR. The therapy of relapsed acute leukaemia in adults. Blood Rev 2004; 18: 39-63.
4. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-Dose cytarabine-based induction chemotherapy. Blood 2010; 116: 5818-5823, quiz 6153.
5. Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG, et al. Results of a HOVON/SAKK donor versus no-Donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-Aged adults: benefits for whom? Blood 2007; 109: 3658-3666.
6. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
7. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, doubleblind, multinational, phase 3 study. Lancet Oncol 2015; e-pub ahead of print 30 July 2015; doi:10.1016/S1470-2045(15)00201-6.
8. Ofran Y, Rowe JM. Treatment for relapsed acute myeloid leukemia: what is new?. Curr Opin Hematol 2012; 19: 89-94.
9. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121: 1077-1082.
10. Gale RP, Lazarus HM. Correcting 2 more myths regarding transplants for AML in second remission. Blood 2014; 123: 794.
11. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940-947.
12. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial951. J Clin Oncol 2012; 30: 2492-2499.
13. Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013; 122: 1384-1394.
14. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, et al. A randomized study of clofarabine versus clofarabine plus low-Dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638-1645.
15. Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389-2395.
16. Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012; 89: 214-219.
17. Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, et al. A phase I study in adults of clofarabine combined with high-Dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012; 18: 432-440.
18. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 2011; 118: 4258-4264.
19. Van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, et al. Phase I-II study of clofarabine-melphalan-Alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 913-921.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
21. Schetelig J, Schaich M, Schafer-Eckart K, Hanel M, Aulitzky WE, Einsele H, et al. Hematopoietic cell transplantation in patients with intermediate and high-risk AML - results from the randomized study alliance leukemia (SAL) AML 2003 trial. Leukemia 2015; 29: 1060-1068.
22. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
23. Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, et al. Retrospective comparison of clofarabine versus fludarabine in combination with high-Dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica 2013; 98: 114-118.
24. Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A, et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012; 88: 52-60.
25. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011; 155: 182-189.
26. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-Term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
27. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
28. Schmid C, Schleuning M, Tischer J, Holler E, Haude K-H, Braess J, et al. Early allo-SCT for AML with a complex aberrant karyotype-results from a prospective pilot study. Bone Marrow Transplant 2012; 47: 46-53.
29. Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-Diagnosed highrisk acute myeloid leukemia. Leukemia 2006; 20: 707-714.
30. Stolzel F, Platzbecker U, Mohr B, Rollig C, Middeke JM, Thiede C, et al. Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. Leukemia 2013; 27: 2068-2072.
31. Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better?. Efficacy comparison between CLAG and MEC regimens. Leuk Res 2011; 35: 301-304.